Answers are grounded in this paper and cite their sources.
In Japanese patients with ACS and hypercholesterolemia inadequately controlled despite statin therapy, from baseline to W36, a numerically greater percent reduction in normalized TAV was observed with alirocumab vs. SoC, which did not reach statistical significance.
No takes yet. Share an insight, caveat, or question.
Ako et al. (2019) studied this question.
Synapse has enriched 3 related papers. Consider them for comparative context: